The results showed continued weight loss of approximately 2.1 kg over 12 weeks, rather than the plateau many had experienced on their previous medication
regulators flagged severe and sometimes fatal pancreatitis cases in 2007-2008 for the earlier GLP-1 drug Byetta (exenatide) and advised clinicians to stop therapy if patients develop persistent severe abdominal pain radiating to the back In the United States, nearly 2,000 GLP-1 lawsuitsprimarily alleging severe gastrointestinal injuries (gastroparesis, bowel obstruction, related complications) after Ozempic, Wegovy, Mounjaro, Trulicity, and other agentsare centralized in federal Multidistrict Litigation (MDL No
The right treatment plan is one that is both medically sound and realistically sustainable for you over the long term
The PIL highlighted their growing repurposing for aesthetic weight loss without India-specific clinical trials, safety evaluations, or regulatory safeguards, citing 82 deaths in the UK, pending lawsuits in the US, and serious health risks including pancreatitis, thyroid cancer, cardiovascular complications, and potential neurological damage
